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Zusammenfassung 
 
Neuroendokrine Tumoren (NET) sind seltene Tumoren mit häufiger Primarusloka-
lisation im GastroEnteroPankreatischen System und in der Lunge. Die Behand-
lungsstrategie der NET hängt von der Tumorlokalisation, dem Grading, dem 
Staging und der hormonellen Funktionalität ab. Durch eine Operation können NET 
bei frühen lokalisierten Erkrankungsstadien kurativ behandelt werden. 
Die palliative Therapie von fortgeschrittenen inoperablen NETs umfasst 
verschiedenen Systemtherapieansätze wie Biotherapie mit Somatostatin-Analoga 
und Interferon-alpha, Peptid Rezeptor Radionuklid Therapie (PRRT), Chemo-
therapie oder molekular zielgerichtete Therapieoptionen . In den letzten Jahren 
wurden signifikante Verbesserungen bezüglich der Tumorkontrolle in der Sys-
temtherapie von NET erreicht, jedoch besteht weiterhin ein Bedarf die molekular-
biologischen Mechanismen der Tumorzelle vertieft zu verstehen und neuartige 
Behandlungsstrategien für eine weiter verbesserte Systemtherapie von NET zu 
entwickeln. Vor diesem Hintergrund wurden im Rahmen der hier vorgelegten 
Dissertationsarbeit zwei neue Strategien der ―targeted therapy‖ in humanen NET 
Zelllinien in vitro untersucht: 
Kapitel 1: 
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Hintergrund und Zielsetzung: Der Wnt/β-Catenin Signalweg spielt eine wichtige 
Rolle bei verschiedenen Malignomen. Strategien zur “targeted therapy” des 
Wnt/β-Catenin Signalwegs sind aktuell in klinischer Entwicklung. Bei NET ist die 
Rolle des Wnt/β-Catenin Signalweg bisher nur unvollständig untersucht-so regu-
liert beispielsweise das Tumorsuppressorprotein Menin (Gen MEN1) in NET Zellen 
den Abbau von Beta-Catenin. Die hier vorgelegte Studie untersuchte die Effekte 
des Porcupine (PORCN) Inhibitors WNT974, des direkten β-Catenin-Inhibitors 
PRI724 und von β-Catenin small interfering (si)RNAs in den humanen neuro-
endokrinen Tumor (NET) -Zelllinien BON1, QGP und H727 in vitro.  
Methoden: Die NET-Zellen wurden mit WNT974 oder PRI724 inkubiert oder mit 
β-Catenin siRNAs transient transfiziert und anschliessend jeweils Zellprolifera-
tionsassays, Durchflusszytometrie, Caspase3/7-Test und verschiedene West-
ern-Blot-Analysen durchgeführt. 
Ergebnisse: Die Behandlung von NET-Zellen mit dem PORCN-Inhibitor WNT974 
inhibierte die Zellvitalität auf dosis- und zeitabhängige Weise signifikant. Analog 
führte auch die Inkubation verschiedener NET-Zelllinien mit dem 
β-Catenin-Inhibitor PRI724 zu einer signifikanten Wachstumshemmung. Der 
siRNA-vermittelte Knockdown der β-Catenin-Expression reduzierte die Vitalität der 
BON1-Tumorzellen, jedoch nicht der H727-Tumorzellen. In den untersuchten NET 
Zelllinien inhibierte der PORCN Inhibitor WNT974 in Westernblot-Analysen nicht 
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nur das “canonical Wnt signaling” (zum Beispiel: LRP6 Rezeptor, β-Catenin und 
downstream targets wie c-Myc und cyclinD1) sondern auch das “non-canonical 
Wnt signaling” (zum Beispiel  pAKT/mTOR-, pEGFR- und pIGFR-Signaling).  
Zusammenfassung und Schlussfolgerung: 
Der Porcupine (PORCN) Inhibitor WNT974 oder der direkte β-Catenin-Inhibitor 
PRI724 führten in NET Zellinien in vitro zu einer spezifischen Hemmung des 
Wnt/β-Catenin Signalwegs und signifikanten antiproliferativen Effekten. Weitere 
präklinische und klinische Studien zur Untersuchung der möglichen Rolle einer 
Inhibition des Wnt/β-Catenin Signalwegs als “targeted therapy” bei NET sollten 
angestrebt werden.  
Kapitel 2: 
Hintergrund und Zielsetzung: Zur weiteren Effektivitätssteigerung der Peptid 
Rezeptor Radionuklid Therapie (PRRT) in der Therapie von NET wird aktuell die 
sogenannte Peptid Rezeptor Chemo Radio Therapie (PRCRT) in präklinischen 
und klinischen Studien evaluiert. Die hier vorgelegte Studie untersuchte die Effekte 
von 5-Fluorouracil (5-FU) jeweils in Kombination mit dem DNA Methyltransferase 
Inhibitor Decitabin (DEC) und dem Histon Deacetylase Inhibitor Tacedinalin (TAC) 
in humanen neuroendokrinen Tumor (NET) -Zelllinien BON1, QGP und H727 in 
vitro.  
Methoden: Die humanen NET-Zelllinien BON1 und QGP1 wurden mit 5-FU alleine 
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oder in Kombination mit DEC oder TAC behandelt. Die Radiosensitivität der Tu-
morzellen wurde nach Inkubation mit den jeweiligen Testsubstanzen  mit Gam-
ma-Bestrahlung (γ-IR) in Dosierungen von 0, 2, 4 oder 6 Gy getestet. Die Soma-
tostatinrezeptor Typ 2 (SSTR2) -Expression und die [68Ga] 
Ga-DOTA-TOC-Radioligandenbindung der NET-Zelllinien wurde untersucht. Zell-
proliferationsassay, Colony-Formation-Assay, Western-Blot-Analyse und Radi-
oligandenbindungsassay wurden hierzu angewandt.  
Ergebnisse: Die Behandlung mit 5-FU plus DEC oder TAC hemmte die Vitalität der 
Tumorzellen im Zellproliferationsassay und regulierte die Expression von 
Zellzyklusmarkern sowie von pro- und antiapoptotischen Proteinen – so wurden  
zum Beispiel aktivierte Caspase-3, cleaved-PARP und p21 induziert, während 
Bcl-2, CHK1, CyclinD1, CDK1 inhibiert wurden. 5-FU allein oder in Kombination 
mit DEC oder TAC steigerte jeweils die Radiosensitivität der Tumorzellen signifi-
kant, wobei in BON1 Zellen Sensibilisierungsverstärkungsverhältnisse (SER) von 
2,19,  3,96 und 9,46 und in QGP1 Zellen Sensibilisierungsverstärkungsverhält-
nisse (SER) von 1,20,  1,31 bzw. 1,87 bestimmt wurden. Die Behandlung mit 
5-FU allein oder plus DEC oder TAC induzierte signifikant die Somatostatinrezep-
tor-Typ-2-Expression (SSTR2) der Tumorzellen und verursachte in vitro eine 
stärkere Bindung des Radioliganden 68Ga-DOTATOC an die Tumorzellen. 
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Zusammenfassung und Schlussfolgerung: Die Kombination von 5-FU mit epige-
netischen Modifiern wie DNMT Inhibitoren oder HDAC Inhibitoren zeigte am Model 
von humanen NET Tumorzellen in vitro: i) antiproliferative Effekte, ii) Radiosensi-
bilisierung iii) Steigerung der Expression der Somatostatin Rezeptor Typ 2 (SSTR2) 
Expression, iv) Steigerung der Radioligandenbindung von 68Ga-DOTATOC. Diese 
präklinischen in vitro Ergebnisse legen nahe, dass eine PRCRT mit 5-FU in Kom-
bination mit epigenetischen Modifiern wie DNMT Inhibitoren oder HDAC Inhibi-
toren eine vielversprechende mögliche Strategie zur weiteren Verbesserung der 
Wirksamkeit der PRRT bei der Behandlung von NETs sein könnte. Weitere präk-
linische und klinische Studien sollten angestrebt werden.  
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Introduction 
 
Novel strategies for targeted therapy in NETs:  
Inhibition of Wnt signaling in neuroendocrine tumors and 
Improving peptide receptor chemoradionuclide therapy (PRCRT) 
by a combination of 5-fluorouracil and epigenetic modifiers 
 
Neuroendocrine tumors (NET), neoplasms frequently occur in the intestine, pan-
creas, lung, or other parts of the human body[1-2]. NET treatment depends on 
primary tumor localization, histopathological classification and grading, staging, 
and hormone secretion [3-6].  
Treatment of NETs, like in most other human cancers, includes surgical resection, 
if diagnosed at the early stage of disease. Surgery can cure NET in early localized 
disease or debulking surgery can relieve symptoms and improve survival in distant 
metastasized disease[7-8]. Systemic treatment options in advanced inoperable 
disease include chemotherapy, targeted therapy with the mTOR inhibitor everoli-
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mus and the multi-tyrosine kinase inhibitor sunitinib, biotherapy with somatostatin 
analogues and interferon alpha, and peptide receptor radionuclide therapy (PRRT) 
[9-11]. Over the last decade, significant improvements have been made for the 
treatment options and clinical outcomes of NET. However, further investigations are 
needed to better understand the molecular mechanisms and to develop novel 
treatment strategies to control NET growth. 
In this doctoral thesis, the first chapter of the research is focusing on Wnt signaling 
pathways, which are involved in the wnt canonical/beta catenin pathway and 
non-canonical pathway. The selective porcupine (PORCN) inhibitor WNT974 has 
exerted therapeutic potential in various preclinical cancer models and clinical trials, 
and also displayed radiosensitizing or chemosensitizing effects [11-17].We further 
explored WNT974 anticancer properties in NET cells. We expected to provide 
evidence regarding the wnt signaling pathway in NET pathogenesis and to develop 
WNT974 as a potential strategy to control NET.  
In this doctoral thesis, the second chapter of the research is to investigate the 
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synergistic effects of 5-fluorouracil (5-FU) combined with DNA metlhyltransferase 
(DNMT) inhibitors or histone deacetylase (HDAC) inhibitors as epigenetic modifi-
ers on radiosensitization and somatostatin receptor 2 (SSTR2) expression and 
binding in human NET cells. 
The PRRT uses a radiopharmaceutical that targets the peptide receptors to deliver 
localized radiotherapy to NET cells and to date, [177 Lu-DOTA0, Tyr3]-octreotate 
(177 Lu-octreotate) is the most frequently used PRRT radiopharmaceutical with 
highly efficient results regarding disease control rate(DCR), PFS as well as OS 
[18-21]. However the ORR of NETs following PRRT is limited to 20-30% [18-21]. 
The essential prerequisite for PRRT of NETs is the high abundance of the peptide 
receptor somatostatin receptor type 2 (SSTR2) on the NET cell surface vs. normal 
cells [22-23].  
The complete remission of patients with metastasized NET after the 177 
Lu-octreotate PRRT is still difficult; thus, additional therapy or targets are needed 
to improve PRRT efficacy on NETs. Indeed, previous studies showed that the 
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combined chemotherapy with PRRT could offer better potential in effective control 
of NETs [24-25], and PRCRT (peptide receptor chemoradionuclide therapy) using 
the concomitant infusion of 5-fluorouracil (5-FU) in comparison to PRRT improved 
treatment responses and OS of patients with NETs [26]. Moreover, combination of 
capecitabine and temozolomide with 177 Lu-octreotate resulted in better PFS of 
patients with metastasized NETs and only modest adverse effects [27].  
Furthermore, DNA methylation/demethylation, and histone acetyla-
tion/deacetylation are fundamental factors in genetic modifacations [28-30]. HDAC 
inhibitors have been developed to treat various human cancers [31-32]. Indeed, 
previous studies revealed that the DNMT inhibitor decitabine(DEC) in combination 
with an HDAC inhibitor tacedinaline(TAC) could synergistically upregulate expres-
sion of somatostatin receptor type 2 (SSTR2), a target of the PRRT, in NETs [33]. 
Other preclinical studies reported that combinations of 5-FU with HDACi or DNMTi 
causes synergistic antitumoral effects in gastric, pancreatic, and colon cancer cells 
[34]. Thus we combined 5-FU with DEC or TAC tand investigated whether these 
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combinations might cause synergistic effects on radiosensitzation, SSTR2 ex-
pression and specific radiologand binding on NET cells. We expected to gain im-
portant preclinical information on novel strategies how to increase the efficacy of 
PRCRT on NETs.  
In this doctoral thesis,  
 data presented in chapter 1 will reveal that the PORCN inhibitor WNT974 
concentration and time-dependently inhibited NET cell proliferation, induced 
G1 or G2 arrest but not apoptosis.WNT974 blocked not only beta catenin 
dependent but also non-canonical Wnt/receptor tyrosine kinase pathways 
(e.g, PI3K/AKT/mTOR, pEGFR/EGFR and pIGFR/IGFR signaling) in NETs 
(beta-catenin inhibitor PRI724 as well).  
 data presented in chapter 2 will demonstrate 5-fluorouracil (5-FU) in com-
bination with the DNA methyltransferase(DNMT) inhibitor decitabine (DEC) 
and the histone deacetylase (HDAC) inhibitor tacedinaline (TAC), to i) sup-
press cell viability and induce apoptosis, ii) to cause radiosensitization in 
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NET cells, at least in part, due to a massively decelerated efficacy of DNA 
damage repair; iii) to upregulate the expression of SSTR2 and iv) to in-
crease radioligand binding of 68Ga-DOTA-TOC in NET cells. Thus this 
study suggest that combinations of 5-FU with epigenetic modifiers might 
constitute suitable approaches to enhance the efficacy of PRRT by com-
bining the radiosensitizing potentials of these drugs on one hand and the 
upregulation of SSTR2 expression and thus, of radioligand binding on the 
other.  
Taken together, the presented date demonstrate  
i) blocking Wnt signaling as a novel strategy for targeted therapy in NETs,  
ii) combination of 5-fluorouracil and epigenetic modifiers to enhance anti-
proliferative effects, radiosensitization,SSTR2 expression and specific 
radioligand binding in NETs and thus being of potential strategy for 
peptide receptor chemoradiation therapy (PRCRT). 
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Future preclinical and clinial trials are required to further investigate the ther-
apeutic efficacy of these novel strategies for NETs.   
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1  Chapter one: Inhibition of Wnt signaling by 
porcupine inhibitor WNT974 in neuroendocrine 
tumors in vitro-antitumoral effect 
 
1.1  Introduction  
The Wnt/beta-catenin signaling cascade play important roles in various cancers 
[35-37]. Wnt/beta-catenin signaling has been revealed to drive tumor cell prolifer-
ation [38-41] and promote cell invasion and migration [42].  
Thus, our research is focusing on the Wnt signaling pathways, which are a group 
of signal transduction proteins that transmit cell surface receptor signaling into the 
cell nucleus, resulting in gene expression and cell proliferation and migration dur-
ing embryo development and tumorigenesis, including NET [43-46]. The Wnt sig-
naling can be further classified into canonical wnt, noncanonical planar cell polari-
ty,noncanonical/receptor tyrosine kinases and noncanonical/calcium pathways, all 
mediated by wnt ligand binding to a Frizzled family receptor [35].  
In the wnt-off state (Figure.1-1), β-catenin is phosphorylated by serine/threonine 
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kinase casein Kinase (CK) or GSK-3, facilitated by scaffolding proteins APC and 
Axin (forming the degradation complex or destruction complex) and could be rec-
ognized by β-TrCP, then finally ubiquitinated for degradation via proteasome. Be-
ta-catenin dependent cascade [47-49] is triggered when the secreted Wnt proteins 
(such as Wnt1 or Wnt3) bind to the FZDs (Frizzled receptors 1-10) as well as the 
LRP5/6 which lead to phosphorylatation of dishevelled (DVL) and further inducing 
the interaction of DVL with Axin, Thereafter, unphosphorylated beta-catenin will 
accumulate and transfer into the nucleus, and bind to TCF/LEF family to activate 
its targeted gene transcription and expression (eg. cyclinD1/D3, c-Myc) [50-59].  
In contrast, non-canonical Wnt signaling is primarily triggered by Wnt5a, wnt5b 
and Wnt11 [43-46], which were further mediated by ROR1/ROR2 and RYK, ex-
erting reciprocal effect with the canonical way (Fig.1-2) [47-49,52-59]. 
Many small molecules [60-66] targeting the wnt siganaling pathway such as Dvl  
inhibitors, beta-catenin destruction complex inhibitors (GSK3 inhibitor, CK1 inhib-
itor), direct beta-catenin inhibitors, PORCN (an o-acetyltransferase, palmitoylation 
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of wnt protein [67-68] inhibitors, tankyrase(TNKS) inhibitors and TCF/LEF inhibitors 
have demontsrated promising anti-tumor effect, especially porcupine inhibitor 
WNT974 as well as beta-cetenin inhibitor PRI724 have already entered clinical 
trials. WNT974 has shown therapeutic potentials in various preclinical models, by 
suppressing the cell viability and distant metastasis or invasion[43-46]. also by 
serving as a chemosensitizer [69] ,immunotherapy modulator or radiosensitizer 
[70]. 
 
 
Fig. 1-1. Wnt carnonical /β-catenin pathway (adapted from reference 52-59). 
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Fig.1-2. Non-canonical Wnt signaling pathway (adapted from reference 52-59). 
 
Moreover, the wnt/β-catenin antagnist PRI724 specically inhibit the binding of 
β-catenin with the coactivatior CREB-binding protein(CBP), and PRI-724 also en-
ters the clinical studies for colon cancer or liver fibrosis [71-72]. 
menin has a high frequency of mutations in pNETs [38,73].When the β-catenin 
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was knockout in Men1 deficient PNETs, the tumor was inhibited and the survival 
time was prolongated in vivo. Some retrospective analysis of human SI-NETs 
[74,75] and pNETs corfirmed the upregulation of wnt signaling as well as the loss of 
APC. 
To sum up, much still needed to be explored in the NETs regarding wnt sigalling 
pathway. In this study, we gained further insight into the wnt canonical and 
non-canonical signaling cascade in NET cells and highlighted the development of 
therapeutic targeting the wnt signaling moleculars(PORCN inhibitors and be-
ta-catenin inhibitors) in NETs treatment.  
1.2  Materials and methods 
1.2.1  cell types and reagents 
All the cell lines(see Table 1-1) were verified the identities via short-tandem repeat 
(STR) sequences by DSMZ (German Biological Resource Centre) [76].WNT974 
(synonym:LGK974) was provided by Novartis corporate(Basel, Switzerland), 
PRI-724 was purchased from Selleckchem (Germany). 
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Cell 
lines 
Pheno-
type 
Sources Medium 
QGP pancreatic 
islet 
Japanese Collection of Re-
search Bioresources Cell Bank 
DMEM+PBS+penicillin/strepto
mycin +amphotericin B 
Bon1 pancreatic Prof.R.G.ke/Marburg,Germany DMEM+PBS+penicillin/strepto
mycin+amphotericin B 
 
H727 bron-
chopul-
monary 
American Type Culture Collec-
tion ,Manassas 
RPMI-1640+penicillin/streptom
ycin+PBS+amphotericin B 
GOT1 midgut 
carcinoid 
Prof.O.Nilsson,Sahlgrenska 
University Hospital Sweden 
RPMI-1640+penicillin/streptom
ycin+FBS+amphotericin B 
+insulin 
Table 1-1. Overview of NET cell lines(human) and cell culture. 
 
1.2.2  Cell proliferation assay 
Firstly, we grown NET cells overnight and administerested them with increasing 
concentrations of the agents(WNT974[1 µM-16 µM] or PRI-724[1 µM -10 µM])  for 
72 h or 144 h, then add 20ul of cell titer blue reagents (Promega,USA), and futher 
incubated for 4 h. cell absorbance rates were determined using an GLOMAX plate 
reader (Promega, Madison, USA).  
1.2.3  Flow cytometric cell cycle distribution assay 
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NET cells were grown and treated with increasing concentration (1 µM-16 µM) of 
WNT974 for 48 h or 72 h and then harvested through trypsinization, centrifugation 
and two washes in PBS. After that, the cells were dissolved in propidium iodide 
(Sigma-Aldrich) and then analyzed and quantified with the BD Accuri C6 Analysis 
machine.     
1.2.4  Caspase-3 and -7 apoptosis experiment 
we seeded NET cells into white-walled plates and cultured overnight, then admin-
istrated them with WNT974 (1 μM and 16 μM respectively) for 72 h and then ex-
posed to Apo-One homogeneous caspase-3/7 regeants (Promega). Firstly, mixed 
the Caspase-Glo®3/7 buffer with the substratethoroughly, then removed 
white-walled 96-well plates out of the incubator, dispensed 100 μl of well-mixed 
reagent per well. After incubating at RT for 2 hours, all the samples were meas-
ured by one Orion II luminometer(Pforzheim, Germany). 
1.2.5  Wound healing and migration assay  
 
 
LMU doctoral thesis                                                   Xifeng Jin 
28 
 
we seeded NET cells into Ibidi culture-insert 2 well dishes (Ibidi, Germany) at a 
density of l.2×105-1.4×105cells per well，then after 24 h, the insert was removed 
and the cell monolayer gap was created . then we treated the NET cells with var-
ious doses of WNT974. We captured and recorded the changes of the wound gap 
under the microscope ( an Zeiss Axiovert 135 TV) equipped with a special camera 
(Zeiss AxioCam MRm, München, Germany) every 24 h. thereafter, NET cell mi-
gration capacity was determined by wound gap measurements at the above men-
tioned time point using Image J software (Bethesda, MD, USA).  
1.2.6  Western blot 
treated NET cells were lysed in the cell lysis buffer (Thermo Scientific, Waltham, 
MA, USA) and quantified. The total cellular protein samples with 50 μg per loading 
were segregated by SDS-PAGE, immobilized to the PVDF membranes (Millipore). 
For western blotting, theses blots were first blocked with clear milk blocking buffer 
(PIERCE, Rockford, USA) for 60 min, then incubated with a variety of primary an-
tibodies( Table.1-2). 
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they were then co-incubated with HRP secondary antibodies (Cell Signaling 
Technology, Germany) at a dilution of 1:25000 for 4 h. The protein bands were 
visualized in enhanced chemiluminescence (ECL) solution followed by exposure to 
Amersham HyperfilmTM (WESTAR Supernova, Cyanagen, Bologna, Italy) and 
quantificated by ImageJ software (NIH, Bethesda, USA).  
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primary antibody   Company primary antbody Company 
total β-catenin Cell signaling #8480 CyclinD1 Cell signaling # 2978 
non-p-β-catenin S45 Cellsignaling #19807 CyclinD3 Cell signaling # 2936 
Ser33/37/Thr41 p-β-catenin  Cell signalin #9561 CDk1 Cell signaling # 9116 
p-β-catenin S552 Cell signaling #5651 CDK4 Cell signaling#12790 
Axin Cell signaling # 2087 CDK6 Cell signaling#13331 
pLRP6S1490 Cell signaling #2568 Chk1 Cell signaling #2360 
LRP6 Cellsignaling #3395 EGFR Cell signaling #4267 
Dvl Cell signaling #3224 pEGFR Cell signaling #3777 
pDvl-2 Cell signaling #3224 IGFR Cell signaling # 3027 
SFRP Cell signaling #3534 pIGFR Y1135 Cell signaling # 3918 
Wnt3a Abcam #28472 Akt Cell signaling #4691 
Wnt5a/b Cellsignaling #2530 pAkt S473 Cell signaling # 4060 
GSK3 Cell signaling # 5676) 4EBP1 Cell signaling # 9644 
pGSK3-a/ß Cell signaling # 8566 p4EBP1 S65 Cellsignaling# 13443 
JNK Cell signaling # 9252 p70S6K Cell signaling # 2708 
pJNKT138/Y185 Cell signaling # 4668 pp70S6K T389 Cell signaling # 9205 
c-Myc Cell signaling #13987 ERK1/2 UBI # 06-182 
Vimentin Cellsignaling #5741 pERK1/2T202Y204 Cell signaling #4370 
ZO-1 Cell signaling #8193 p53 Santa Cruz -126 
Menin Santa Cruz -374371 pmTOR S2448 Cell signaling #2971 
cyclin B1 Cell signaling # 12231 Neurotensin Santa Cruz -377503 
S6 Cell signaling #2217 pS6 S240/4 Cell signaling #5364 
Bcl-2 Abcam #694 Chk2 Cell signaling #6334 
AIF Santa Cruz -13116 E-Cadherin Cell signaling #3195 
P21 Waf1/Cip BD #610233   
Table 1-2.Multiple primary antibodies measured in westernblot. 
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1.2.7  β-catenin siRNA and GSK3β siRNA transfection 
We ordered small β-catenin siRNA, GSK3β siRNA or non-targeting siRNA from 
Dharmacon RNA Technologies(On-Target plus SMART Pool, Cat #L-003482, 
-003484, Cat #D-001810, respectively, Dharmacon USA). appropriate number of 
Bon1 and H727 cells were seeded and incubated for 16-18 h, and then subjected 
to  optimal transfection with GSK3beta siRNA(50 nM) or β-catenin siRNA(25 nM 
for Bon1,and 75 nM for H727 ) by using DharmaFECT 2(bon1) or 3 (H727) trans-
fection reagent for 72 h. then exposed to WNT974 for 72h after transfection. 
Thereafter, the cells were collected and subjected to cell viability and Western 
blotting assays.  
1.2.8  Statistical analysis 
Each experiments was conducted in triplicates and was repeated more than once 
and the data were summarized as the mean and SDs (or SEM). Statistical analysis 
was assessed by the student t test, Dunnett’s t test and ANOVA with SPSS 16.0 
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software for Windows (Chicago), A p value <0.05 was considered statistically sig-
nificant. 
1.3  Results  
1.3.1  WNT974 dose and time dependently suppressed the 
growth of NET cells 
NET cell viability after WNT974 treatment was firstly evaluated. As shown in Fig. 
1-3, WNT974 inhibited the cell viability in all three cell lines in a concentration- and 
time- dependent manner. At the end of 144 h incubation the cell viability was re-
duced to 58.20% ±12.53%, 63.99%±11.90%, 56.42%±10.84% in Bon1, QGP and 
H727 respectively. The IC20 values of WNT974 were 5.4 μM, 7.8 μM and 10.1 μM 
in Bon1, H727 and QGP respectively.  
1.3.2  Suppression of NET cells migration by WNT974  
We next examined the effect of WNT974 on regulation of NET cell migration ca-
pacity. The wound healing assay showed that WNT974 only suppressed the mi-
gration of Bon1 and QGP cells at the largest dosage, while showed no changes in 
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H727 cells (Fig.1-4). At the gene level, e-cadherin, vimentin and the tight junction 
protein ZO-1[77-79]were further analyzed. Though no significant change was ob-
served in E-cadherin after WNT974 treatment, the vimentin level was markedly 
downregulated and ZO-1 was moderately increased in NET cells. 
 
Fig. 1-3. WNT974 decreased NET cell proliferation. 
(*p<0.05, **p<0.01, and ***p<0.001). 
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Fig.1-4. Effect of WNT974 on regulation of NET cell migration. 
(wound healing assay,*p<0.05, **p<0.01, and ***p<0.001). 
 
 
1.3.3  Cell cycle re-distribution after WNT974 treatment 
WNT974 lead to G1 phase arrest in a dose (1 uM -16 uM) dependent mode in 
Bon1 and H727. The percentage of G0/G1 phase population increased from 61.4% 
to 75.43% in BON1, from 57.56% to 74% in H727 respectively after WNT974 
treatment. Subsequently, we observed a marked reduction of S phase population, 
from 14.09% to 8.036%, and from 12.80% to 7.38% respectively) in these 2 cell 
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lines. Meanwhile the evident accumulation in the G2 phase was observed in QGP 
cells after WNT974 treatment (from 15.24% to 25.13%), accompanied by de-
creased G0-G1 phase(from 77.93% to 68.07%)(Fig. 1-5-1-8). 
 
 
Fig. 1-5. Effect of WNT974 on cell cycle distribution. 
(NET cells were treated with or without Wnt974 for 72 h,then subjected to FACS, 
*p<0.05, **p<0.01, and ***p<0.001). 
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Fig.1-6. Effect of WNT974 on regulation of caspase-3/7 activity in NET cells. 
(NET was treated with wnt974 for 72 h and then subjected to caspase-3/7 apopto-
sis assay, which shows a mean percentage of caspase 3/7 activity compared to 
the untreated control (100% ± SD). 
 
 
Correspondingly, WNT974 reduced the expression levels of cyclins (cyclin D1/D3/ 
B1), cyclin-dependent kinases (cdk1/4/6), and checkpoint kinase-1 (Chk1) in a 
dose-dependent manner. Meanwhile, WNT974 treatment reduced the expression 
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of cyclin kinase inhibitor proteins, like p21Cip1 and p53, although level of AIF was 
no significant changes in these three NET cell lines (Fig. 1-5-1-8). 
On the other hand, caspase -3/7 activity assay didn’t show any significant changes 
in apoptosis in NETs, also, the percentages of sub-G1 phase were not significantly 
increased (Fig.1-5-1.8). These data indicate that WNT974 antitumor activity was to 
induced by NET cell arrest at G1 or G2/M phase and suggest that combination of 
WNT974 with other apoptosis-inducers is needed to achieve the maximal an-
ti-tumor activity.  
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Fig. 1-7. WNT974 regulated cell cycle related proteins(western blot). 
(Bon1, QGP, and H727 cells were treated with or without Wnt974 (0.25 µM to 16 
µM) for 72 h and then exposed to western blotting.) 
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Fig. 1-8. Quantitation of western blotting of WNT974 on regulation of cell 
cycle markers in NET cells.(relative changes in protein bands were measured by 
densitiometric analysis with the control). 
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1.3.4  Suppression of Wnt/β-catenin signaling by WNT974  
Our data showed that WNT974 treatment of NET cells downregulated expression 
of LRP/pLRP6 and DVL2/pDVL2, whereas WNT974 upregulated Axin in Bon1 and 
QGP cells and SFRP1( a antagonist of the Wnt signaling) only in H727 cells (Fig. 
1-9;1-10). Levels of Wnt1, Wnt3a and Wnt5a/b were only slightly decreased 
(Fig.1-9;1-10). Furthermore, WNT974 treatment dose- and time-dependently re-
duced level of non-phosphorylated-β-catenin, total β-catenin, and related down-
stream targeting proteins( c-Myc/cyclinD1/cyclinD3, or others), while β-catenin 
phosphorylation at Ser33/Ser37/Thr41 gradually recovered back to the basal lev-
els after 48 and 72 h treatment with WNT974 (Fig.1-9;1-10). However, these 
changes did not equally occur, which was obvious in Bon1, but less in H727 cells, 
indicating that WNT974 effects on Wnt signalling was cell type-specific. 
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Fig. 1-9. Effects of WNT974 on inhibition of wnt/beta-catenin signaling. 
Bon1, QGP, and H727 cells were treated with or without Wnt974 (0.25 µM ,1 µM, 4 
µM to 16 µM) for 72 h and then exposed to western blotting. 
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Fig.1-10. Quantitative western of suppressing wnt pathway after WNT974 
treatment. 
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1.3.5  Inhibition of the pAKT/mTOR, pEGFR pIGFR and pJNK by 
WNT974 
Since the modes of action of WNT974 on beta-catenin pathway were not unique in 
all three NET cells tested, we further assessed whether other prominent cell pro-
liferation signaling could mediate the effects of WNT974. Our data showed that 48 
h or 72 h treatment of NET cells with WNT974 had significant reduction of pAKT, 
S6, pS6, and p70S6K, whereas WNT974 was able to induce p-mTOR in these 
three cell lines (Fig. 1-11; Fig. 1-12).  
WNT974 treatment also inhibited level of EGFR/pEGFR, and IGFR/pIGFR in Bon1 
and QGP1 while reduced pERK in and H727 and QGP1. However, JNK/pJNK was 
inhibited only in Bon1 cells. These results further indicated that the inhibitory ef-
fects of WNT974 may be dependent on cell lines(Fig. 1-11; Fig. 1-12).  
 
 
 
 
 
LMU doctoral thesis                                                   Xifeng Jin 
44 
 
 
Fig.1-11. Effects of WNT974 on the inhibition of the pAKT/mTOR, MAPK/ERK, 
pEGFR and pIGFR pathways in NET cells. 
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Fig.1-12.Representative quantification analysis of western blot of 
pAKT/mTOR, MAPK/ERK, pEGFR and pIGFR pathways post WNT974 treat-
ment(*p, **p and ***p stand for <0.05, <0.01, p<0.001 respectively). 
 
 
 
LMU doctoral thesis                                                   Xifeng Jin 
46 
 
1.3.6  The regulatory mechanisms of β-catenin siRNA and 
PRI724 (a molecule acting as a selective β-catenin inhibitor) on 
NET cells  
We explored effect of β-catenin silencing and PRI724 on reduction of NET cell 
viability.Our data showed that β-catenin knockout markedly decreased the viability 
of Bon1 cells, but not that of H727 (Fig.1-13).At the protein levels, β-catenin siRNA 
also downregulated expression of CDK1, CHK1, DVL2 but upregulated pGSK3β 
(Fig.1-13). Combination of WNT974 with β-catenin siRNA could further suppress 
expression of these proteins, and also reduced cMyc and cyclinD1/cyclinD3, pLRP, 
pAKT, pERK1/2 and others. 
As expected, PRI724, suppressed the NET cell growth significantly(Fig.1-14; 
Fig.1-15). PRI724 treatment also downregulated expression of non-p-β-catenin 
and β-catenin phosphorylation at S552 as well as cell cycle, and EMT-related 
proteins (cyclinD1, cyclinD3, CDK1/4/6, Chk1, cmyc and neurotensin) (Fig.1-14; 
Fig.1-15). Interestingly, PRI724 also downregulated expression levels of Wnt3a 
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but increased pGSK3beta (Fig.1-14; Fig.1-15). These data confirmed that PRI724 
inhibited the NET cells in a similar way to that of WNT974. 
 
 
 
Fig. 1-13. β-catenin siRNA regulated NET cell viability together with protein 
expressive levels. 
( Bon1 and H727 cells were transfected with β-catenin or negative control siRNA 
for 72 h and then subjected to the MTT assay and westernblot. *p, **p and ***p  
stand for <0.05, <0.01, p<0.001 respectively) 
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Fig. 1-14. Effect of PRI724, a selective β-catenin inhibitor, on the regulation 
of NET cell viability and protein expression. 
( A, Cell viability MTT assay. B, Western blot. Bonl cells were treated with or 
without PRI724 (up to 10 µM) for 48h or 72 h and then subjected to A and 
B,*p<0.05, **p<0.01, and ***p<0.001 compared with that of controls.) 
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Fig. 1-15. Quantification of western blot analysis of PRI724 on inhibition 
Bon1 cells. 
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1.3.7  Effects of GSK3β siRNA with or without WNT974 on regu-
lation of NETs  
Next, we examined whether inhibition of GSK3β could enhance WNT974 sup-
pression of NET cell viability. When the GSK3β siRNA was transfected to Bon1 or 
H727 , then approximately 80-90% GSK3β protein was knocked out, which led to a 
significant increase in NET cell viability (Fig.1-16). However, addition of WNT974 
brought cell viability and p-GSK3β expression back to the control levels (Fig.1-16), 
indicating that WNT974 antitumor activity was through GSK3β inhibition. High ex-
pressions of p-GSK3β after WNT974 was detected in all the 3 cell lines, thus we 
postulated that the increase of p-GSK3β was cell dependent. 
Indeed, GSK-3β siRNA transfection with or without WNT974 treatment significantly 
reduced β-catenin phosphorylation at Ser33/37/Thr41 and levels of 
ERK1/2/pERK1/2, AKT/pAKT, p70S6K, pJNK, pEGFR, and pIGFR (Fig.1-16). 
Knockdown of GSK3β expression also caused up-regulation pJNK in BON1 but 
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downregulation in H727. All in all, these further revealed that the suppression of 
WNT974 was in partially but not completely GSK3β-independent way.  
 
 
Fig. 1-16. GSK3 β siRNA regulated NET cell viability and protein expression. 
(NET Bon1, and H727 cells transfected with GSK3β or negative control siRNA in 
presence or absence of WNT974 for 72 h and then subjected to A and B. A, Cell 
viability MTT assay . B, Western blot.) 
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1.3.8  The protein expression of neurotensin and menin was 
regulated by WNT974  
Next, we explored whether WNT974 can regulate the expression of neuroendo-
crine tumor markers. Neurotensin (NT) has been reported to induce NET cell pro-
liferation [80-81], Our western blot data showed that WNT974 and PRI724 both 
downregulated NT expression (Fig.1-8; Fig.1-14;1-15).  
In addition, WNT974 slightly downregulated menin expression in all three NET cell 
lines, and after the knockout of β-catenin expression, menin was shown to be 
downregulated.Thus, we postulate that menin expression may be 
β-catenin-dependent. In contrast, we observed no constantly reproducible effects 
on Menin expression (Fig. 1-8; Fig.1-14;1-15). 
1.4  Discussion 
NETs are a group of diversified neoplasms with different malignant potential. Mo-
lecularly, NET demonstrate altered expressiion patterns of various genes and 
proteins, including Wnt/β-catenin, Ras/MAPK/ERK, Akt/mTOR, and Notch signal-
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ing [9,82-83]. Indeed, our current study demonstrated that WNT974 concentration 
and time dependently suppressed the NET cell growth and lead to G1 and G2 
phase arrest. At the molecular level, WNT974 treatment inhibited the 
Wnt/β-catenin, pAKT/mTOR, MAPK/ERK, pEGFR and pIGFR signaling pathways 
in NET cells. Furthermore, β-catenin siRNA reduced NET cell viability and down-
regulated the expression of cyclinD1, CDK1, but upregulated the expression of 
pGSK3β.  
PRI724 treatment also downregulated the expression of non-p-β-catenin at Ser45, 
phosphorylated β-catenin at S552 and Ser33/37/T41 as well as cell proliferation, 
cell cycle, and EMT-related markers. In contrast, the knockdown GSK3β expres-
sion significantly increased NET cell viability, whereas the addition of WNT974 
treatment antagonized the effect of GSK3β siRNA on cell viability and p-GSK3β 
expression.Altogether,our current study demonstrated that targeting Wnt/β-catenin 
signaling could potently induce antitumor effects against NET cells, although there 
was no apoptosis involved in WNT974-treated NET cells in vitro.  
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Recent studies showed that Wnt signaling activation or inhibition depended on 
receptor context or distinct receptors in different cell types [69,70]. We revealed 
that the expression of pLRP6, pDVL2, and wnt3a/5ab was downregulated by 
WNT974 in all three cell lines, which was indicative that the Wnt canonical and 
non-canocical pathways were important in NET cells. The Axin1 protein expres-
sion initially rised and then gradually decreased after consistent WNT974 treat-
ment. This biphasic process might be because i) Axin crosstalks with many other 
signaling pathways(e.g. TGF-β/Smad3 cascade[84]; ii) Axin is a concentra-
tion-limiting factor in the β-catenin degradation complex[85-86]; and iii) The ex-
pression of Axin1 was cell type-dependent [84,85-86]. In our current study, we 
demonstrated that WNT974 decreased the expression of non-phosphorylated 
β-catenin, total β-catenin, which primarily resulted from an increase in the pro-
teasome-mediated degradation of β-catenin. Furthermore, our current study 
showed that with the exception of wnt canonical signaling, the pAKT/mTOR, pERK, 
pEGFR and pIGFR signaling pathways were also downregulated by WNT974 in 
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NET cells, indicating that the dual or multiple suppression of different signaling 
pathways could be more feasible and efficient to control NET. 
In the study, WNT974 caused G0/G1 arrest in Bon1 and H727，whereas a G2 
phase arrest  was observed in QGP, demonstrating the heterogeneity of different 
types of NETs. Further analysis showed that WNT974 downregulated cy-
clinD1/cyclin D3, CDK1/2/4, chk1/2.  
Meanwhile in all the 3 cell lines no concurrent upregulation of apoptosis was ob-
served. All these findings suggest that WNT974 should be further evaluated in 
combination with chemotherapy, radiotherapy and other molecular targeting inhib-
itors to further enhance its anti-tumor effects.  
GSK3β could function as oncogene as well as tumor suppressor in various can-
cers. In NETs we have proved previously that decreased active GSK3 or in-
creased inactivated GSK3beta was indicative of antitumor effect in NETs 
[87,88-90].  
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Other previous studies revealed that GSK3 was essential in wnt/beta catenin 
cascade,  although only a small percentage (<10%) of the total GSK-3 in cells is 
to engage in the canonical Wnt signaling[91-92]. The presence of phosphory-
lated-GSK3β(Ser9)  means the deactivation of GSK3β; however, the overex-
pressive p-GSK3β does’t mean loss of GSK3β, and an increase of p-GSK3β was 
cell-dependent(as indicative of the aspirin treated colorectal cancer cells) 
[93,94,95].  
Our current study showed that GSK-3β silencing enhanced cell viability of Bon1 
and H727 and that WNT974 treatment could block the impact of GSK-3β knockout 
on NET cell growth and protein expressions, indicating that the WNT974-reduced 
NET cell growth occurred through the inhibition of GSK3β signaling. Moreover, our 
current data showed that GSK-3β knockdown downregulated the level of phos-
phorylated β-catenin, cyclinD1, CDK1, neurotensin, pLRP (Fig.1-16); however, the 
co-treatment of these cells with WNT974 further suppressed the expression of 
these markers. In addition, GSK-3β siRNA reduced the expression pEGFR, pAKT, 
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pERK, pJNK but upregulated the expression of c-Myc and p-mTOR (Fig.1-16). 
Altogether, the downregulation of AKT/pAKT, ERk/pERK,JNK/pJNK, IGFR/pIGFR 
and EGFR/pEGFR by WNT974 was GSK3 independent as well as cell-line de-
pendent. 
The reasons for this discrepancy remain to be clarified and might be discussed as 
follows:   
i) a counter-regulatory mechanism or negative feedback effects as a result of 
inhibition of Wnt canonical signaling might lead to downregulation of GSK3 
and restoration of beta catenin signaling.   
ii) the increase of p-GSK3β might be cell- and tissue- context dependent.  
iii）  GSK3 is envolved in various signaling pathways and crosstalks with many 
other signaling pathways.  
iv)    GSK3α and GSK3β are not inter changeable ,which are both necessary for 
the entire function of GSK3.  
Menin seems to be a negative regulator of beta-catenin, and in MEN1-deficient 
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knockout mice beta-catenin is activated in pNETs while vice versa conditional be-
ta-catenin knock-out decreased tumourigenesis of pNETs[40,96] .More clinical 
studies are essential to investigate the precise interaction between menin and 
beta-catenin in NET. 
Our current study primarily sought to assess the antitumor activity of WNT974 in 
NET cells in vitro. Although we also provided the underlying molecular events 
triggered by this inhibitor in NET cells, the major limitations of our current study are 
that i) We did not monitor the Wnt-regulated transcriptional activity using a lucif-
erase reporter assay; ii) We did not knock down each of these key gene pathway 
genes to assess the precise targets of WNT974 and PRI724 action; and iii) We did 
not assess the combination of these two agents or their combination with other 
chemotherapeutic drugs on NET cells. 
In conclusion, our current study provides information on the molecular events of 
WNT974 and PRI724 anti-cancer activities in NET cells in vitro. Our current ob-
servations lead to two possible conclusions, i.e.,  
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i) WNT974 inhibits Wnt/β catenin signaling and 
ii) WNT974 exerts an inhibitory effect on NET cells by downregulating the 
MAPK/ERK, PI3K/AKT/mTOR, pEGFR, and pIGFR non-canonical signaling 
cascades. 
However, the context-dependent effects of WNT974 on NET need further in-
vestigation. 
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2  Chapter two: Combination of 5-fluorouracil 
(5-FU) with DNMT inhibitors or HDAC inhibitors as 
epigenetic modifiers has synergistic effects on ra-
diosensitization and somatostatin receptor 2 (sstr 
2) expression in human neuroendocrine tumor 
cells 
 
2.1  Introduction  
Treatment of NETs, includes surgical resection, if diagnosed at the early stage of 
disease, while advanced disease requires systemic treatment strategies as bio-
therapy, chemotherapy, targeted therapy and peptide receptor radionuclide ther-
apy(PRRT) [97-98,26]. 
Peptide receptor radionuclide therapy (PRRT) uses radiopharmaceuticals that 
target peptide receptors e.g. somatostatin receptor type 2 (SSTR2) expressed on 
the tumor cell surface to deliver specific binding of the radiopharmaceutical and 
radiotherapy to NETs [99-101]. To date, [177 Lu-DOTA0, Tyr3]-octreotate 
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(177Lu-DOTA-TATE) is the most frequently used radiopharmaceutical to be used 
for PRRT in NETs [99-101]. 
 PRRT in patients with NETs causes an objective response rate (ORR) less than 
30%, while the disease control rate (DCR) is much higher due to common stable 
disease following PRRT[99-101]. PRRT significantly improves OS and PFS in 
NETs and has limited side effects[99-101] .  
Complete remission of NETs following PRRT with [177Lu-DOTA0, Tyr3]-octreotate 
(177Lu-DOTA-TATE) is a rare event in 2-7% and also partial remissions occur only 
in 19 -29 % of patients [99-102]; optimized treatment strategies are imperative to 
further improve PRRT efficacies in NETs. An essential requirement for PRRT of 
NETs is the abundance of the SSTR receptors expressed in NET cells[100-101], 
although the predictive value of somatostatin receptor expression measured as 
SUV in a pretherapeutic PET/CT seems modest and variable [[100-104].  
 Several clinical studies have demonstrated that PRCRT using the combination of 
chemotherapy with 5-fluorouracil[26], capecitabine[105], or capecita-
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bin/temozolomide [106], plus PRRT could offer highly efficient objective tumor 
response and effective tumor control of NETs [101,105-106]. These effects of 
PRCRT were suggested to be mainly due to radiosensitizing effects[101], while 
radionuclide uptake during PRRT has been reported to be not significantly altered 
by concomitant chemotherapy with capecitabin /temozolomide[27].  
Furthermore, DNA methylation/demethylation and histone acetyla-
tion/deacetylation are fundamental factors in genetic modifacations[27]. DNA me-
thyltransferase(DNMT) transfers methyl groups to genomic DNA, usually at CpG 
islands, to methylate DNA and silence gene transcription [107]. Moreover, the 
HDAC transfers acetyl groups to induce histone to tightly bind to genomic DNA and 
therefore, acetylation and de-acetylation will regulate gene expression[108-109]. 
HDACi or DNMTi has been established to treat various human cancers [31-32]. 
Combination of HDACi with DNMTi, conventional cytotoxic chemotherapy and 
radiotherapy has been investigated in various cancers and has been suggested to 
be additive or synergistic [33]. 
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In neuroendocrine tumors, epigenetic alterations and epigenetic modulation by 
HDAC inhibitors（HDACi） and DNMT inhibitors(DNMTi) as potential treatment 
strategy have been studied  and reviewed recently [44,110-113]. Preclinical stud-
ies in NETs demonstrated that many DNMT inhibitors e.g. decitabin (DEC) and 
HDAC inhibitors eg. valproic acid (VPA) or tacedinalin (TAC) could induce the ex-
pression of somatostatin receptor type 2 (SSTR2) [114-115] and promote the 
binding of somatostatin ligands to the targeted tumor cells [114-115]. DEC and 
TAC were demonstraed to be the most potent drugs investigated and their com-
bination also demonstrated synergistc effects [114].  
Therefore, we explored the underlying molecular basis of 5-fluorouracil (5-FU) in 
combination with or without DEC or TAC on cytotoxicity, apoptosisis, cell cycle 
changes, somatostatin receptor type 2(SSTR2) expression and somatostatin lig-
and binding of 68Ga-DOTA-TOC in various NET cell lines in vitro. Radiosensitizing 
effects as well as increased somatostatin receptor expression were demonstrated 
for each compound tested and synergistic effects were found combining 5-FU and 
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epigenetic modifiers. Thus, these preclinical in vitro data suggest to further inves-
tigate the possible role of 5-fluoropyrimidine based chemotherapy in combination 
with epigenetic modifiers and PRRT as a novel strategy in peptide receptor 
chemoradiotherapy (PRCRT) in NETs.  
2.2  Material and Techniques 
2.2.1  Cell lines, reagents and cytotoxicity assay 
The cell culture methods used were similar to those in chapter 1 (please refer to 
chapter one). 5-FU, DEC, and TAC were all obtained from Selleckchem (Munich, 
Germany) and stock solution of these agents were prepared by dissolving them in 
dimethyl sulfoxide (DMSO). 68Ga-DOTA-TOC was produced by using SomaKit 
TOCTM , which was ordered from AAA Inc (Saint-Genis-Pouilly, France. The 68Ga 
was eluted from a GalliaPharm® Ge-68/Ga-68 generator from Eckert & Ziegler 
(Berlin, Germany).   
To assess the effects of DEC or TAC on enhancement of 5-FU anti-tumor activity, 
NET cells were treated with these two drugs concurrently at a fixed ratio of ap-
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proximating their individual IC20 (drug dose that reduce 20% of cell viability on day 
6) for 144 h and the doses of 5-FU were selected based on our previous studies 
[116]. Cell Titer Blue was utilized for testing cytotoxicity as described in chapter 
one .  
2.2.2  Tumor cell colony-forming analysis  
(1) Bon1 and QGP tumor cells were plated into six-well plates. 
(2) Cells were grown and exposed to low concentrations (approximately IC10 or 
IC20) of 5-FU, DEC, TAC, 5-FU+DEC, 5-FU+TAC,and DEC+TAC for 24 h. 
(3) Cells were exposed to various doses (0Gy, 1Gy, 2Gy, 4Gy, 6Gy) by using a 
XStrahl RS225 radiation cabinet (XStrahl Inc., Camberley, UK).  
(4) Cells were further incubated for 2 weeks (Bon1 cells) or 3 weeks (QGP1 cells) . 
(5) Afterwards NET cells were fixed with 70% ethanol and then stained with 0.3% 
methylene blue for 0.5-1 h.  
(6) Then the colonies (greater than 50 cells) were counted and the surviving frac-
tions (SF) were calculated vs. the plating efficiency.  
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(7) Linear-quadratic (LQ) models were used to fit the survival curves, the sensiti-
zation enhancement ratio(SER) was determined as followings:SF= 
1-(1-exp[−D/D0])
N ;SER SF2= the SF2 value of DMSO control group /the SF2  of  
various treatment group [117-120] . 
2.2.3  H2AX/53BP1 immunofluorescent staining after 
-irradiation 
First, we seeded BON1 into 24-well plates with the number of 40.000 cells per well, 
then the second day, we administrated the cells with DEC (0.5 µM) or 5-FU (1.0 
µM), we also used DMSO as negative control. After 24 h, we discard the drugs and  
changed new freshed medium, and exposed the NET cells to gamma irradiation at 
a dose of 2 Gy. Next, we used 3.7% isotonic formaldehyde to fix NET cells at var-
ious time points (0 h, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h) and stained them for 
53BP1/histone H2AX (H2AX, p S139) .We captured 31 z-stacks images with an 
inter-stack interval of 250 nm by immunofluorescence microscopy(ZEISS Observ-
er Z1 ,Carl Zeiss, Germany). Then we utilized the ZEN software(Carl Zeiss, Ver-
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sion 2.3) to perform the deconvolution. We counted the numbers of H2AX foci of 
20 nuclei manually, and calculated the means  s.d for the different treatment 
groups at all time points. 
2.2.4  Protein isolation and Western blotting  
The westernblotting assay was performed as described in chapter1 please refer to 
part 1). We tested the following antibodies: anti-SSTR2 (Abcam), PARP, cleaved 
PARP, caspase-3, cleaved caspase-3(Cell Signaling), or CDK1/CDK4/CyclinD1/ 
CyclinB1/Chk1 /p53 /Bcl-2 /p21Waf1/Cip1(see Table.1- 2,Chapter one) .  
2.2.5  Cell cycle assay by flow cytometry 
The flow cytometry analysis was performed as described in chapter one (please 
refer to part 1). 
2.2.6  68Ga-DOTATOC uptake assay 
The BON1 and H727 cells were treated with 5FU+DEC, or 5FU+TAC for 72h (us-
ing the same concentration as used in the westernblot experiments), then the su-
pernatant was removed and cells were further cultured with the internalization 
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medium (DMEM) for 1 h, and then we added with 68Ga-DOTA-TOC-labeled pep-
tides (4 kBq) in a final peptide concentration of 2.5 pmol/L, then further cultured the 
cells to indicated time points ( 0.5, 2, and 4 h ) at 37°C. Excessive non-labeled 
68Ga-DOTO-TATE (1000 fold) was used as the nonspecific internalization control. 
The cells were then exposed to 1M NaOH at 37°C for 10 minutes at least 3 times 
to remove the cells from the dishes. The gamma ray-counter (PerkinElmer) was 
used to measure the radioactivity, which was expressed as the ratio of measured 
to total amount of radioactivity and normalized to the total protein levels.  
2.2.7  Statistical analysis 
Statistical analysis was performed as described in chapter1 please refer to chapter 
one). CalcuSyn 2.1 (Biosoft, USA) [121-123] were used to evaluate the synergistic 
additive or antagonistic effects of the 5FU combined with DEC or TAC on NET 
cells.  
2.3  Results 
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2.3.1  Dose-dependent reduction of NET cell proliferation after in 
vitro treatment with DEC or TAC 
In this study, we first treated different NET cell lines with DEC and TAC and found 
that these two drugs were able to individually reduce NET cell growth at a 
dose-dependent fashion. After 144 h treatment, cells treated with TAC showed a 
median viability of 11%, 35.9%, and 42.04% for Bon1, QGP, and H727 cells, re-
spectively (Fig.2-1), while cells treated with decitabine showed a median viability of 
49%, 88%, and 84% in Bon1, QGP, and H727 cells, respectively. The IC50 of DEC 
and TAC in all these 3 cell lines is shown in Table 2-1. 
 
NET cell lines IC50 
 Decitabine(µM) Tacedinaline(µM) 
Bon1 15.19 3.58 
QGP — 11.97 
H727 — 15.68 
Table 2-1. IC50 of Decitabine and Tacedinaline in NET cells. 
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Fig. 2-1. DEC and TAC decreased NET cell viability. 
  
 
2.3.2  5-FU plus DEC or TAC exerted synergistic effects on cell 
proliferation in vitro  
Next, we assessed the combination therapy of 5-FU with DEC or TAC on NET cell 
proliferation in vitro. Not only 5-FU plus DEC but also 5-FU plus TAC caused syn-
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ergistic antiproliferative effects in all cell lines included (Fig.2-2). The combination 
index (CI), calculated as the fractional cell growth inhibition (FA) as a function of 
the CI, was less than 1 in the combination of 5FU with DEC [the mean CI (the 
FA50) was 0.323, 0.80, and 0.859, respectively for these three cell lines], indicat-
ing that the treatment with two different drugs indeed showed the synergistic ef-
fects on these NET cells. The combination of 5-FU with TAC could reach the CI of 
0.556, 0.782, and 0.70, respectively in Bon1, QGP, and H727 cells (Fig.2-2 and 
Table.2-2).  
Cell lines Combination therapy ED50 ED75 ED90 
Bon1 5FU+DEC 0.32 0.20 0.16 
 5Fu+TAC 0.55 0.53 0.62 
QGP 5FU+DEC 0.80 0.84 0.88 
 5FU+TAC 0.78 0.91 1.03 
H727 5FU+DEC 0.85 0.70 0.58 
 5FU +TAC 0.70 0.55 0.48 
Table 2-2. Combination index(CI) values of 5-FU plus DEC or TAC in NET 
cells. 
 
 
LMU doctoral thesis                                                   Xifeng Jin 
72 
 
 
 
 
Fig. 2-2. 5-FU combination with DEC or TAC synergistically suppressed NET 
cell viability. 
(The isobologram plots and combination index were calculated based on different 
combination treatments.) 
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2.3.3  5-FU combined with DEC or TAC synergistically inhibited 
the clonogenic survival after -irradiation in NET cells  
We next explored whether the combinations of 5-FU with DEC or 5FU with TAC  
had synergistic effects on radiosensitizing NET cells.  
Therefore, we treated Bon1 and QGP1 cells with low concentrations of 5-FU (1 µM) 
with or without DEC or TAC at doses of 0.5 µM for DEC and 2.5 µM for TAC (ap-
proximately IC10 to IC20 dosage) and subjected them to clonogenic assay. The 
low dose of 5-FU (1 µM) was based on our previous studies[116] and preliminary 
work performed in our laboratory confirmed its radiosensitizing effect.  
The sensitization enhancement ratios (SERs) for 5-FU, DEC, TAC, 5FU + DEC , 
5FU + TAC  and DEC + TAC，in Bon1 cells were achieved to be 2.19, 1.10, 1.10, 
1.27, 3.96, 9.46, and 1.10, respectively, and 1.20, 1.12, 1.01, 1.31, 1.87, and 2.42 
respectively, in QGP1 cells.  
Thus, 5-FU plus TAC treatment was the most effective approach in reducing the 
clonogenic survival in BON1 cells with superiority to combinations of 5-FU and 
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DEC, or DEC and TAC, or each single drug (Fig.2-3). In contrast, DEC plus TAC 
was most effective in QGP1 cells, followed by 5-FU plus DEC and 5-FU plus TAC 
vs. each single agents (Fig.2-3) 
 
Fig. 2-3. 5-FU plus DEC or TAC reduced cell colonic formation of NETs. 
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Fig. 2-4  5FU and DEC caused persistent immunofluorescence staining of  
H2AX/53BP1. (A)representative picture of phospho-H2AX and 53BP1 immuno-
fluorescence staining after irradiation. Green stands for phospho-H2AX; Red 
stands for 53BP1; Blue stands for Hoechst 33342 (2ug/ml). (B) the clearance of 
γ-H2AX foci.*p<0.05, **p<0.01, and ***p<0.001(5FU/DEC vs DMSO control) .@ 
p<0.05( 5FU vs DEC). 
 
2.3.4  5-FU and DEC reduced the efficiency of  DNA damage 
repair after γ-irradiation   
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The combined administration of 5-FU or decitabine with γ-irradiation significantly 
suppressed efficiency of DNA damage repair in BON1 cells.   
Both, 5FU or DEC caused an increased persistence of γH2AX-/53BP1 DNA 
damage foci even 24h following the irradation(p<0.001), which indicated that both 
drugs decreased the efficacy of DNA damage repair. 5FU was significantly superior 
to DEC in displaying DNA damage response foci at 4/6/8/12/24 h respectively 
(p<0.01, Fig. 2-4). 
2.3.5  Effects of 5-FU combination with DEC or TAC on NET cell 
cycle re-distribution and gene expression  
In Bon1 cells, 5-FU or 5-FU plus DEC treatment induced a significant rise of G2 
phase and a subsequent reduction of G1 and S phase, while 5-FU combination 
with TAC caused tumor cell arrest at the G1 cell cycle (Fig.2-5). Similar findings 
also occurred in H727 cells but not in QGP1, i.e., 5FU plus DEC caused accumu 
lation of the G1/M phased cells (Fig.2-5), whereas treatment of cells with 5-FU and 
TAC did not result in significant changes in the proportion of the G1 and S phases. 
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These data indicate that the differential effects of these drug combinations on cell 
cycle distribution could be cell -type-dependent. 
 
Fig. 2-5. Effects of 5-FU combination with DEC or TAC on NET cell cycle 
re-distribution (*p, **p and ***p stand for <0.05, <0.01, p<0.001 respectively). 
 
In radiation therapy, the G2/M phased cells are the most radiosensitive [124]; thus, 
treatment of NET cells with 5-FU plus DEC or TAC could sensitize NET cells to 
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radiation therapy. At the protein level, 5-FU with TAC decreased expression of 
Chk1, CDK4, and CyclinD1 more significantly compared to the control group or 
each single agent (Fig.2-6). In contrast, pretreatment 5FU with DEC maintained 
the high levels of Chk1 and CDK4 expressions, although slightly decreased cy-
clinD1, CDK6 expression (Fig.2-6 , Fig.2-7) 
2.3.6  Effects of 5-FU combination with DEC or TAC on NET cell 
expression of apoptosis related proteins  
Western blot data showed that incubation of Bon1 cells with 5-FU, DEC, 5-FU + 
DEC, TAC, or 5-FU + TAC induced expression of cleaved-PARP 2.8-, 3.2-, 4.4-, 
0.7-, and 1.4-fold , indicating 5-FU plus DEC being much stronger than either sin-
gle drug (Fig.2-6,Fig.2-7). Moreover, in H727 cells, expression of the cleaved 
PARP was increased by 1.17 (5-FU alone), 1.55 (DEC alone), 1.89 (5-FU + DEC), 
1.25 (TAC alone), 2.34 (5-FU + TAC) folds, respectively. 
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Fig. 2-6. Effects of 5-FU combination with DEC or TAC on NET cell expres-
sion of SSTR2, apoptosis-related protein and cell cycle-related protein. 
 
 
The cleaved caspase 3 level was slightly upregulated in BON1, QGP as well as 
H727 cells ,while it significantly increased in GOT1 cells after 5-FU + DEC/5-FU + 
TAC treatment(Fig.2-6, Fig.2-7). In accordance, expression of the anti-apoptotoc 
protein Bcl-2 was reduced to 0.63 (5-FU), 0.75 (DEC), 0.61 (5-FU + DEC), 0.84 
(TAC), and 0.70 (5-FU + TAC), respectively in Bon1 cells and by 1.0, 0.83, 0.68, 
0.71, and 0.72, respectively in H727 cells (Fig.2-6, Fig.2-7).  
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Fig 2-7. Representative quantitative westernblot of 5FU plus DEC or TAC on 
SSTR2, apoptosis and cell cycle related proteins in NET cells. 
(relative changes in protein bands were measured by densitiometric analysis with 
the DMSO control，*p, **p and  ***p stand for <0.05, <0.01, p<0.001 respectively). 
 
 
 
 
LMU doctoral thesis                                                   Xifeng Jin 
81 
 
2.3.7  Induction of SSTR2 expression after treatement with single 
drugs or their combination in NET cells  
As shown in Fig.2.5, SSTR2 expression was promoted not only by DEC, TAC or 
5FU alone, but further increased by 5FU+DEC, 5FU+TAC and DEC+TAC combi-
nations in GOT1, Bon-1 and H727 cells, but not in QGP cells (Fig.2-6, Fig.2-7).  
Thus, 5-FU plus DEC was the most effective in Bon-1 cells for upregulation of 
SSTR2 (8.56 fold increase), superior to that of 5-FU plus TAC (8.29 fold increase) 
or DEC plus TAC (8.31 fold increase), or either single drug (Fig.2-6 , Fig.2-7). In 
GOT1 cells, 5-FU plus TAC was also the most effective combination, whereas 
5-FU plus DEC exerted a lesser effect than that of DEC plus TAC.  
Moreover, in H727 cells, the highest efficacy was observed after combination of 
5-FU plus TAC (1.75 fold increase), while 5-FU plus DEC (1.52 fold increase) and 
single drugs were slightly less effective (Fig. 2-6, Fig.2-7). Thus, these data sug-
gest that SSTR2 upregulation might be cell-line dependent. 
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2.3.8  Effects of 5-FU combination with DEC or TAC on NET cell 
uptake of somatostatin receptor2  
We next explored whether drug-induced SSTR2 expression might also cause an  
increased binding of 68Ga-DOTA-TOC to tumor cells. 
Drug-induced SSTR2 upregulation was most profound in Bon1 cells followed by 
H727 cells. Therefore, the subsequent binding experiments, were performed in 
these two cell lines. Our data showed that not only 5-FU plus TAC but also 5-FU 
plus DEC  time-dependently increase the uptake of 68Ga-DOTATOC without 
hitting a peak (Fig.2-8).  
For the longest period of 4 h, a significant increase of uptake was observed in both 
5-FU + DEC and 5-FU+TAC groups ( 13.0% ± 0.43% and 19.06% ± 1.1% vs. 2.96% 
±0.21% of the control, p<0.001; respectively). The competitive non-labeled 
68Ga-DOTO-TATE blocking experiment revealed, that nonspecific uptakes of the 
5-FU+DEC and 5-FU+TAC treated groups were only 0.48%±0.17%, 1.065%±0.23% 
respectively at 4 h.  
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Redundant qualitative results could also be observed in H727 cells, but in this cell 
line 5-FU plus DEC or 5-FU plus TAC revealed only an about twofold increase of 
68Ga-DOTA-TOC intake (Fig. 2-8). 
 
 
Fig. 2-8. 5-FU plus DEC or TAC promoted intake of SSTR2 in NET cells. 
A(Bon1) and B(H727), the total internalized activity of  68Ga-DOTATOC. The 
intake is expressed as a percentage of added radioactivity (AR)/mg of protein. In 
each blocking experiment, 1,000 fold excess of the non-labeled 68Ga-DOTO-TATE 
was added into cell culture. ***p<0.001, **p<0.01 and *p<0.05. 
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2.4  Discussion 
PRRT with targeting radiopharmaceutical agents like 177Lutetium-DOTATOC or 
177Lutetium- DOTATATE, has been mostly used to clinically manage NETs, but 
the objective response rates (ORRs) were only between 20% to 30% [114]. Thus, 
search for combination with other agents has been actively pursued including: i) 
radiosensitizing by 5-fluoropyrimidine based chemotherapies in clinical studies  
[26,86,104-105] or various molecular targeting therapy in preclinical studies  
[125-127], ii) epigenetic modification by DNA methyl transferase inhibitors (DNMTi), 
i.e. decitabine (DEC)] or histone deacetylase inhibitors (HDACi) i.e. tacedinaline 
(TAC)] to improve upregulation of SSTR[114-115]and radioligand binding [114-115] 
of the tumor cell in preclinical studies; iii) development of alpha targeted therapy 
rather than using the beta pharmaceuticals [128-130]; iv) using somatostatin an-
tagonists rather than agonist [128,131]. 
In several clinical studies in patients with NETs further improvement of the thera-
peutic efficacy of PRRT has been reported by peptide receptor chemoradiation 
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therapy (PRCRT) [101] with fluoropyrimidine-based chemotherapeutic regimens 
using the combination of PRRT and chemotherapy with 5-fluorouracil [48], cape-
citabine [49], or capecitabin/ temozolomide [106,27].  
Several preclinical studies from Taelman and Veenstra et al revealed that DNMTi 
and HDACi alone upregulate SSTR at the level of mRNA and protein expression, 
and enhance the SSTR2 mediated radioligand binding[114-115]. In addition, their 
combination showed addictive effects on increasing the SSTR2 expression and 
radioligand binding in animal models [114]. 
In the current preclinical in vitro study, we now systematically investigated the ef-
fects of the chemotherapeutic agent 5-FU alone and in combination with DEC or 
TAC on human NET cell lines with respect to reduction of cell viability; radiosensi-
tizing; induction of apoptosis; promoting SSTR2 expression and increasing the 
radioligand binding of the tumor cell. 
 Our results demonstrate, that i) DEC or TAC dose-dependently reduce NET cell 
viability in vitro, while 5-FU in combination with DEC or TAC further synergistically 
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reduces NET cell viability; ii) 5-FU in combination with DEC or TAC is most effi-
cient to reduce viability of gamma-irradiated NET cells in the colony formation 
assay, suggesting a significantly enhanced radiosensitizing effect in comparison to 
single drug treatment; iii) DEC and 5FU in particular resulted in great persistence of 
γH2AX-/53BP1 DNA damage after irradiation. iv) 5-FU in combination with DEC or 
TAC increases apoptosis subG1 events and induces expression of apopto-
sis-related proteins PARP or caspase-3 cleavage in NET cells; v) while 5-FU, DEC 
or TAC alone caused a modest increase in SSTR2 expression in NET cells, the 
combinations of DEC plus TAC as well as 5-FU plus DEC or 5-FU plus TAC in-
duced a significant increase in SSTR2 expression in NET cells. vi) Binding assays 
with 68Ga-DOTA-TOC also demonstrated that 5-FU plus DEC or 5-FU plus TAC 
induced a significant increase of specific radioligand binding of NET cells. Thus, 
our current data suggest that the combination of 5-FU plus DEC or 5-FU plus TAC 
might be an efficient approach to enhance PRRT by combining radiosensitizing 
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effects and upregulation of somatostatin receptor (sstr) 2 expression and specific 
radioligand binding of the tumor cell.  
5-FU is an analog of uracil and in cells, it will be incorporated into genomic DNA to 
inhibit the thymidylate synthase, leading to prevention of cells from synthesis of 
DNA, RNA, and protein [132,133]. 5-FU-induced tumor cell radiosensitization has 
been reported to be mediated by an increase in killing S phase cells [132]. How-
ever, other mechanisms may also mediate 5-FU-induced tumor cell radiosensitivity. 
In the current study, 5-FU could induce NET cell apoptosis and arrest NET cells at 
the G2 cell cycle and if 5-FU was combined with DEC or TAC, NET cell viability 
was synergistically reduced. Indeed, the combination of DNMT inhibitors and 
HDAC inhibitors has been already demonstrated to show synergistic antitumor 
effects [134]. This is because DNMT and HDAC inhibitors exhibited an overlapping 
role in alteration of gene expression and other cell functions. DNMTs or other 
methylated-DNA binding proteins could facilitate histone deacetylation by recruit-
ing HDAC activity [135,136]. Molecularly, HDAC helps DNA methylation through 
 
 
LMU doctoral thesis                                                   Xifeng Jin 
88 
 
recruiting histone H3 lys9 methyltransferase [136]. The methylated genomic DNA 
will lose the transcriptional activity. In this regard, they could synergistically reduce 
cell activity in cell growth and gene expressions to enhance radiosensitivity 
[137,138].  
In our current study, we expanded our observations showing that treatment of NET 
cells with 5-FU and DEC alone or 5-FU plus DEC induced NET cells to increase 
expression of cleaved PARP, cleaved caspase3, and p21waf1/cip1, but reduce 
anti-apoptotoc bcl2 protein expression, indicating induction of NET cell apoptosis. 
Our current finding is consistent with previous studies of HDAC inhibitors in NETs 
[110,139-140]. Furthermore, 5-FU is a cell cycle-dependent anticancer agent[141] 
and 5-FU plus DEC or 5-FU plus TAC also decreased expression of CyclinD1, 
CDK1/4/6, and CHK1 in this study. Thus, treatment of NET cells with 5-FU in 
combination with DEC or TAC could reach a synergistic effect on NET cells. 
It has been demonstrated that the induction or upregulation of SSTR by DNMTi or 
HDACi was not only observed in human NET cell lines but also in human hepa-
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tocellular carcinoma[142], pancreatic adenocarcinoma [143], small cell lung can-
cer [144]   and prostate cancer LNCaP cells[145]. It has been established that 
HDACi or DNMTI regulated the activation and transcription of the upstream pro-
moter of the human SSTR2 (hSSTR2). Meanwhile, ours is the first study to reveal 
that 5-fluorouacil or other fluoropyrimidine agents with or without DEC/TAC can 
also promote SSTR2 expression in NETs. 
In summary and conclusion, these preclinical in vitro data suggest, that the com-
bination of 5-FU plus DEC or 5-FU plus TAC might be an efficient approach to 
enhance PRRT by combining radiosensitizing effects and upregulation of somato-
statin receptor (sstr)2 expression and specific radioligand binding of the tumor cell. 
Future clinical trials are essential to confirm the therapeutic efficacy of this novel 
strategy for peptide receptor chemoradiation therapy (PRCRT) combining the 
conventional chemotherapeutic drug 5-FU and an epigenetic modifier as the DNA 
methyl transferase inhibitor decitabine or the histone deacetylase inhibitor 
tacedinaline.  
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3.  Conclusions and outlook 
 
Chapter one:  
Besides the suppression of canonical Wnt/β-catenin signaling pathway, the 
PORCN inhibitor WNT974 also inhibited the non-canonical wnt pathways, 
i.e.pEGFR, pIGFR and PI3K/AKT/mTOR pathways. Meanwhile, the antitumor ac-
tivity of WNT974 was partially GSK3β-dependent and partially 
GSK3β-independent. 
ß-catenin inhibitor PRI-724 also exerts potent antitumoral effects in NETs in vitro. 
Molecular targeted therapy with wnt signaling inhibitors/beta-catenin inhibitors in 
NETs should be further explored in preclinical animal models and in early clinical 
studies. In the future next generation sequenzing (NGS) of tumors might provide 
predictive markers to select patients with predictive mutations (i.e. menin or APC) 
for personalized treatment.  
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Chapter Two: 
Decitabine (DEC) or Tacedinaline (TAC) dose-dependently reduced NET cell via-
bility in vitro; 5-FU combination with DEC or TAC synergistically reduced NET cell 
viability and colony formation; DEC and 5FU in particular resulted in great 
persistence of γH2AX-/53BP1 DNA damage foci after irradiation.5-FU or 5-FU plus 
DEC treatment induced a drastic rise of G2 phase with subsequent decline of S 
and G1 phase; 5-FU combination with DEC or TAC upregulated the expression of 
apoptosis-related markers cleaved caspase3 or cleaved PARP; Most importantly, 
5-FU or 5-FU combination with DEC or TAC upregulated SSTR2 expression and 
induced the binding of  68Ga-DOTA-TOC in NETs.  
Future preclinical and clinical trials are urgent to confirm the therapeutic efficacy of 
this novel strategy for peptide receptor chemoradiation therapy (PRCRT) combin-
ing the conventional chemotherapeutic drug 5-FU and DNA methyltransferase 
inhibitors or histone deacetylase inhibitors in NETs. 
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RNA Ribonucleic Acid 
CTNNB  Catenin, beta-1 
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